AN2 THERAPEUTICS INC (ANTX)
US0373261058 - Common Stock
AN2 Therapeutics to Participate at Upcoming Investor Conferences
AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan
Thursday 8/15 Insider Buying Report: ANTX, WRBY
ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips AN2 Therapeutics (NASDAQ:ANTX) just reported results for the second quarter of ...
ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q2 2024
ANTX stock results show that AN2 Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights
Why Is AN2 Therapeutics (ANTX) Stock Down 35% Today?
AN2 Therapeutics stock is down on Friday after ANTX investors learned of the company terminating its EBO-301 Phase 2/3 clinical trial.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
We have all of the biggest pre-market stock movers that traders need to know about on Friday with the latest news breakdowns!
ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q1 2024
ANTX stock results show that AN2 Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips AN2 Therapeutics (NASDAQ:ANTX) just reported results for the first quarter of 2...
AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights
ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q4 2023
ANTX stock results show that AN2 Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips AN2 Therapeutics (NASDAQ:ANTX) just reported results for the fourth quarter of ...
AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
Transitioning HBV cure programs into multiple late-stage combination studies with interim results throughout 2024 and 2025 informing Company's registrational...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AN2 Therapeutics, Inc. ("AN2" or the "Company") (NASDAQ: ANTX). Such investors...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AN2 Therapeutics, Inc. ("AN2" or the "Company") (NASDAQ: ANTX). Such investors...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AN2 Therapeutics, Inc. ("AN2" or the "Company") (NASDAQ: ANTX). Such investors...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AN2 Therapeutics, Inc. ("AN2" or the "Company") (NASDAQ: ANTX). Such investors...
AN2 Therapeutics stock falls as Leerink cuts on trial setback
AN2 Therapeutics (ANTX) shares dropped as Leerink Partners downgraded the company after it paused enrollments in a clinical trial. Read more here.